Gilead Reports Positive Data from Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
December 07, 2013 at 20:03 PM EST
Gilead Sciences (Nasdaq: GILD ) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that among patients with chronic lymphocytic leukemia (CLL)